References
Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807
Quintás-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109–3117
Duong VH, Komrokji RS (2014) The role of pacritinib in the management of myelofibrosis. Expert Rev Hematol 7(3):325–332
Verstovsek S, Mesa RA, Salama MA et al (2013) Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia Vera (PV), and essential thrombocythemia (ET). Blood 122:665
Barosi G, Mesa R, Finazzi G et al (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121(23):4778–4781
Zhou T, Georgeon S, Moser R et al (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia 28(2):404–407
Heine A, Held SAE, Daeke SN et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192–1202
Besancenot R, Roos-Weil D, Tonetti C et al (2014) JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood 124(13):2104–2115
Tiedt R, Coers J, Ziegler S et al (2009) Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 113(8):1768–1777
Ng AP, Kauppi M, Metcalf D et al (2014) Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci U S A 111(16):5884–5889
Acknowledgments
The study was supported by BolognAIL, ELN, AIRC, progetto Regione-Università 2010–2012, FP7, NGS-PTL Project.
Conflict of interest
The authors declare that they have no competing interests.
Authorship
All authors wrote the paper and gave final approval to the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Polverelli, N., Catani, L., Vianelli, N. et al. Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms. Ann Hematol 94, 1585–1587 (2015). https://doi.org/10.1007/s00277-015-2397-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2397-9